Theravance Biopharma Inc Q1 2025 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Marc Frahm - TD Cowen - Analyst : Thanks for taking my questions. Maybe I'll have one kind of on ampreloxetine, and then I'll have a follow-up on the commercial performance for Rhonda. To start on the ampreloxetine side, I appreciate your comments that you had some time before NDA has even filed, let alone launching the product in the US. So you have some time to maybe adjust to whatever policies may come out. Can you just kind of give a status update of like where the current plan for manufacturing is in terms of locations and then where that IP resides? Is that in Ireland? Or has that already been placed in the United States?

Question: Marc Frahm - TD Cowen - Analyst : Okay. That's helpful. And then, Rhonda, I mean, from the slides you presented, I mean, the performance of your team and the hospital team seems tremendous in terms of the growth that we're seeing there over the past year. Just what efforts are you kind of tweaking over time to maybe try to increase the rate at which those hospital prescriptions turn into filled chronic prescriptions once the patient leaves? Rhonda Farnum - Theravance Biopharma Inc - Senior Vice President - Commercial and Medical Affairs, Chief Business Officer Thanks, Marc. And I'm glad you appreciate the work and results the team is delivering. The importance and the critical nature of that transition of care patient, given the increasing volume of hospital patients is, obviously, the whole purpose of why we are focused in that side of care. And in partnership with Viatris at the local geographies, the teams are working very closely, not only in recognizing where patients are leaving the hospital with the script in hand to ensuring that they're getting the support through patient fulfillment program, getting that patient to the right fulfillment site, and then ensuring the follow-up with the maintenance care. So it is a handoff and very, very close partnership that's occurring at the local level.

Question: Marc Frahm - TD Cowen - Analyst : Okay. Thank you.